pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
itepekimab · news · pharmadog
← back to itepekimab
News mentioning itepekimab
10
stories
15d
Sanofi scraps STAT6 degrader from Nurix just 2 months after entering clinic
fiercebiotech
20d
Sanofi considering ‘moonshot’ treatments as M&A targets to survive Dupixent patent cliff
fiercebiotech
Oct 1, 26
Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor
biospace
Aug 18, 26
Regeneron ends eye disease study due to antibody's safety profile
biospace
Aug 18, 26
Regeneron ends eye disease study due to antibody's safety profile
biospace
Aug 6, 26
Sanofi pauses mid-stage lung study amid new CEO’s ‘rigorous portfolio prioritization’
biospace
Aug 5, 26
Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’
fiercebiotech
Jul 31, 26
Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
biopharma dive
Jul 30, 26
Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chest
biospace
Jul 30, 26
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
fiercebiotech